Modeling sequence-sequence interactions for drug response

MOTIVATION Genetic interactions or epistasis may play an important role in the genetic etiology of drug response. With the availability of large-scale, high-density single nucleotide polymorphism markers, a great challenge is how to associate haplotype structures and complex drug response through its underlying pharmacodynamic mechanisms. RESULTS We have derived a general statistical model for detecting an interactive network of DNA sequence variants that encode pharmacodynamic processes based on the haplotype map constructed by single nucleotide polymorphisms. The model was validated by a pharmacogenetic study for two predominant beta-adrenergic receptor (betaAR) subtypes expressed in the heart, beta1AR and beta2AR. Haplotypes from these two receptors trigger significant interaction effects on the response of heart rate to different dose levels of dobutamine. This model will have implications for pharmacogenetic and pharmacogenomic research and drug discovery. AVAILABILITY A computer program written in Matlab can be downloaded from the webpage of statistical genetics group at the University of Florida. SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.

[1]  K. Gabriel,et al.  Ante-dependence Analysis of an Ordered Set of Variables , 1962 .

[2]  E. Lander,et al.  Mapping mendelian factors underlying quantitative traits using RFLP linkage maps. , 1989, Genetics.

[3]  R. Doerge,et al.  Empirical threshold values for quantitative trait mapping. , 1994, Genetics.

[4]  I. Hall,et al.  Implications of Genetic Variability of Human β2-adrenergic Receptor Structure , 1995 .

[5]  N. Schork,et al.  Who's afraid of epistasis? , 1996, Nature Genetics.

[6]  M. Lynch,et al.  Genetics and Analysis of Quantitative Traits , 1996 .

[7]  P. Eriksson,et al.  Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. , 1997, The Journal of clinical investigation.

[8]  D. A. Mason,et al.  A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.

[9]  David R. Anderson,et al.  Model selection and inference : a practical information-theoretic approach , 2000 .

[10]  M. Bhaskara Rao,et al.  Model Selection and Inference , 2000, Technometrics.

[11]  M. Kenward,et al.  Parametric modelling of growth curve data: An overview , 2001 .

[12]  G. Casella,et al.  Joint linkage and linkage disequilibrium mapping of quantitative trait loci in natural populations. , 2002, Genetics.

[13]  G. Casella,et al.  Functional mapping of quantitative trait loci underlying the character process: a theoretical framework. , 2002, Genetics.

[14]  J. Ott,et al.  Power and Sample Size Calculations for Case-Control Genetic Association Tests when Errors Are Present: Application to Single Nucleotide Polymorphisms , 2002, Human Heredity.

[15]  R. Kerwin,et al.  Pharmacogenetic and Pharmacogenomic Research in Psychiatry: Current Advances and Clinical Applications , 2003 .

[16]  E. Snyder,et al.  The human obesity gene map: the 2002 update. , 2003, Obesity research.

[17]  J. Giraldo.  Empirical models and Hill coefficients. , 2003, Trends in pharmacological sciences.

[18]  G. Casella,et al.  Molecular Dissection of Allometry, Ontogeny, and Plasticity: A Genomic View of Developmental Biology , 2003 .

[19]  Jason H. Moore,et al.  The Ubiquitous Nature of Epistasis in Determining Susceptibility to Common Human Diseases , 2003, Human Heredity.

[20]  A. Serretti,et al.  Predicting Response to Lithium in Mood Disorders , 2003 .

[21]  J. Cheverud,et al.  A Mechanistic Model for Genetic Machinery of Ontogenetic Growth , 2004, Genetics.

[22]  G. Casella,et al.  Sequencing Complex Diseases With HapMap , 2004, Genetics.

[23]  G. Casella,et al.  A General Framework for Analyzing the Genetic Architecture of Developmental Characteristics , 2004, Genetics.

[24]  E. Snyder,et al.  The Human Obesity Gene Map the Human Obesity Gene Map: the 2003 Update , 2022 .

[25]  J. Johnson,et al.  A statistical model for functional mapping of quantitative trait loci regulating drug response , 2004, The Pharmacogenomics Journal.

[26]  C. Haynes,et al.  Quantifying the Percent Increase in Minimum Sample Size for SNP Genotyping Errors in Genetic Model-Based Association Studies , 2005, Human Heredity.

[27]  G. Casella,et al.  Functional Mapping of Quantitative Trait Loci Underlying Growth Trajectories Using a Transform‐Both‐Sides Logistic Model , 2004, Biometrics.

[28]  P. Donnelly,et al.  Genome-wide strategies for detecting multiple loci that influence complex diseases , 2005, Nature Genetics.

[29]  J. Johnson,et al.  Sequencing drug response with HapMap , 2005, The Pharmacogenomics Journal.

[30]  Josemir W Sander,et al.  Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Wei Zhao,et al.  A non-stationary model for functional mapping of complex traits , 2005, Bioinform..

[32]  M. Pericak-Vance,et al.  Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease , 2005, Human Genetics.

[33]  R. Wu,et al.  Detecting Sequence-Sequence Interactions for Complex Diseases , 2006 .

[34]  R. Wu,et al.  Functional mapping — how to map and study the genetic architecture of dynamic complex traits , 2006, Nature Reviews Genetics.